1COR Stock Overview

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. More details

1COR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 54.5% below our estimate of its fair value

Earnings are forecast to grow 14.96% per year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Has a high level of debt

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Cencora, Inc. Competitors

Amplifon

BIT:AMP

€4.3b

McKesson

NYSE:MCK

US$86.8b

Cardinal Health

NYSE:CAH

US$35.5b

DiaSorin

BIT:DIA

€5.2b

Price History & Performance

Summary of share price highs, lows and changes for Cencora
Historical stock prices
Current Share Price	US$249.00
52 Week High	US$250.35
52 Week Low	US$250.20
Beta	0.60
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-0.14%

Recent updates

Shareholder Returns

	1COR	IT Healthcare	IT Market
7D	-3.8%	9.4%	3.1%
1Y	n/a	17.6%	13.6%

Return vs Industry: Insufficient data to determine how 1COR performed against the Italian Healthcare industry.

Return vs Market: Insufficient data to determine how 1COR performed against the Italian Market.

Price Volatility

Is 1COR's price volatile compared to industry and market?
1COR volatility
1COR Average Weekly Movement	n/a
Healthcare Industry Average Movement	5.5%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.9%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1COR's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1COR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1871	44,000	Bob Mauch	www.cencora.com

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Cencora, Inc. Fundamentals Summary

How do Cencora's earnings and revenue compare to its market cap?
1COR fundamental statistics
Market cap	€49.45b
Earnings (TTM)	€1.53b
Revenue (TTM)	€279.71b

31.9x

P/E Ratio

0.2x

P/S Ratio

Is 1COR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1COR income statement (TTM)
Revenue	US$310.23b
Cost of Revenue	US$300.01b
Gross Profit	US$10.22b
Other Expenses	US$8.53b
Earnings	US$1.69b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	8.74
Gross Margin	3.29%
Net Profit Margin	0.55%
Debt/Equity Ratio	665.9%

How did 1COR perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

24%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 21:45
End of Day Share Price	2025/05/12 00:00
Earnings	2025/03/31
Annual Earnings	2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Gregory Bolan	Avondale Partners
Eric Coldwell	Baird

Cencora BIT:1COR Stock Report